Biomarker Assays are becoming more crucial for clinical research and biologics testing. These tests can be employed as a surrogate / pharmacodynamics (PD) marker for monitoring clinical efficacy, helping to identify a lead candidate and understanding the mechanism of action of a medicine. In order to shorten follow-up times, biomarker assays are also helpful for detecting intermediate success endpoints.
A specific biomarker assay can be used to give a preliminary indication of a drug’s effectiveness. In turn, this knowledge can help to lessen pressures associated with development deadlines and resources by optimizing clinical development programmes and reducing attrition rates.
Omics or Immuno-Assays, ADA, FACS, IHC, Bio-Analytics, Specialty Assays
Variety of specialty assays complement the usual lab pathology done on clinical and nonclinical studies that support immuno-therapies or gene therapies
Xbiom maintains awareness of standards maintained in globally accepted registries and provide automated transformations of biomarker assay data to standard notation
Examples of omics categories managed in Xbiom ontologies include:
